MedTrace Logo

Effect of Fertility-sparing Therapy of Early Endometrial Cancer

NCT03538704 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-05-29

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of Fertility-sparing Therapy of Early Endometrial Cancer.

Conditions

Interventions

DRUG

Metformin

Metformin is given to patients 1-1.5g/d.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Maternal and Child Health Hospital of Hubei Province

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Jianliu Wang, Professor · Department of Obstetrics and Gynecology, Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2020-03-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538704 on ClinicalTrials.gov